The US regulator has started a review of Roche's supplemental biologics license application (BLA) for Gazyva/Gazyvaro ...

After six years at the helm of the Medicines and Healthcare products Regulatory Agency (MHRA), Dame June Raine will step down ...

Welcome to the first edition of Changing Faces for 2025. January kicked off the year with a flurry of notable leadership ...

Anderson is expecting 2025 to be a pivotal year for his turnaround plan – which revolves around the removal of management ...

The decision to acquire Chimerix comes just a few months after Jazz claimed FDA approval for Ziihera (zanidatamab), its ...

The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto, which brought in ...

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure ...

The Windsor Framework marks a significant change in the UK's post-Brexit regulatory space, particularly for the ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...

Bluesky’s less formal and more community-driven environment also offers an opportunity for experimentation. Unlike X, where ...

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

The UK pharma industry has warned that declining access to new medicines in England – down 10% in recent years – will ...